UnknownPhase 4

Somatostatin in Living Donor Liver Transplantation

56 participantsStarted 2019-12

Plain-language summary

Aim of the study is to investigate the safety and the efficacy of somatostatin as liver inflow modulator in patients with end-stage liver disease (ESLD) and clinically significant portal hypertension (CSPH) undergoing Adult-to-Adult living donor liver transplantation (A2ALDLT).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patients (\> 18 years old) undergoing Adult-to-Adult Living donor Liver Transplantation (LDLT) (right or left lobe) * Indication for LDLT: End Stage Liver Disease with Portal Hypertension (HVPG ≥ 10mmHg) Exclusion Criteria: * Complete portal vein thrombosis (pre-operative or intraoperative diagnosis) * Hepatopulmonary hypertension * Adult-to-Adult Living donor liver transplantation for Fulminant hepatic failure * Recipients of multiple solid organ transplants * History of cardiac arrhythmias

What they're measuring

Portal venous flow changes

Timeframe: Day 0 - At the end of liver transplantation surgery, before skin closure

Trial details

NCT IDNCT04107428

SponsorKing Faisal Specialist Hospital & Research Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-08

Contact for this trial

Roberto Troisi, MD, PhD

+966(0)11-4482123 roberto.troisi@unina.it

View on ClinicalTrials.gov More End Stage Liver DIsease trials